Opus Genetics (IRD) announced the appointment of Rob Gagnon, CPA, MBA, as CFO. Gagnon joins Opus from Remix Therapeutics, where he served as CFO and led the company’s finance function, strategic financing process, fundraising efforts and IPO preparation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Promising Developments and Financial Stability Drive Buy Rating for Opus Genetics
- Opus Genetics announces FDA clearance of IND application for OPGx-BEST1
- Opus Genetics: Promising Clinical Trials and Strategic Partnerships Drive Buy Rating
- Opus Genetics reports Q2 EPS (12c) vs (30c) last year
- Opus Genetics Secures Funding for Gene Therapy Development